Community pharmacists could reduce the clinical and economic burden of diabetes by participating in diabetes management. Pharmacists' roles in collaboration with other health care professionals should be understood before any community pharmacy—based programs focusing on diabetes management are designed and implemented.
Methods:
A sample of primary health care physicians, community pharmacists, and nurses and dieticians from Diabetes Centres in the Capital Health District of Nova Scotia were interviewed on their perceptions of community pharmacists' role in diabetes care. A semistructured format was used. Data were compiled and analyzed descriptively, and are reported here in terms of the roles of community pharmacists in this setting.
Results:
A total of 18 health care professionals were interviewed: 8 (44%) primary health care physicians, 6 (33%) community pharmacists, and 4 (22%) nurses and dieticians. All responses were analyzed, and six general roles for community pharmacists were identified, such as education about drug therapy (83% of respondents), followed by providing information to patients about glucose monitoring and healthy lifestyles (67% of respondents).
Conclusion:
In a pilot project (n = 18), Nova Scotia health care professionals supported pharmacists' role in diabetic care, such as educating patients about drug therapy.
Get full access to this article
View all access options for this article.
References
1.
ColmanR. The cost of chronic disease in Nova Scotia. Glen Haven (NS): GPI Atlantic; 2002. Available: www.gov.ns.ca/health/downloads/chronic.pdf (accessed April 8, 2003).
2.
HarveyDHoodEMcCutcheonVChronic disease prevention: a worthwhile investment. Winnipeg, Manitoba: Alliance for the Prevention of Chronic Disease; 1996. Available: www.apcd.mb.ca/pdfs/a_worthwhile_investment.pdf (accessed July 11, 2005).
3.
MeltzerSLeiterLDanemanD1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ1998; 159(8 Suppl):S1–29.
4.
CampbellRK. DCCT opens new opportunities for pharmacists. Calif Pharm1993;Dec:26–7.
5.
Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med1993; 329:977–86.
6.
OhkuboYKishikawaHArakiEIntensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract1995; 28:103–17.
7.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837–53. Erratum in: Lancet 1999;354:602.
8.
BerringerRShibleyMCHCaryCOutcomes of a community pharmacy-based diabetes monitoring program. J Am Pharm Assoc1999; 39:791–7.
9.
SchapanskyLMJohnsonJAMajumdarSRThe burden of pharmacotherapy for patients with type 2 diabetes in northern Alberta — data from the DOVE Study [abstract]. Can J Clin Pharmacol2001; 8 (1):22.
10.
CranorCChristensenD. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc2003; 43 (2):149–59.
11.
CherryJCMoffattTPRodriquezCDrydenK. Diabetes disease management program for an indigent population empowered by telemedicine technology. Diabetes Technol Ther2002; 4 (6):783–91.
12.
BeneyJBeroLABondC. Expanding the roles of outpatient pharmacists: effects on health services utilization, costs and patient outcomes [Cochrane review]. In: The Cochrane Library; Issue 4, 2003. Chichester (UK): John Wiley & Sons, Ltd.
13.
WalkerDRLandisDLSternPMVanceRP. Disease management positively affects patient quality of life. Manag Care Interface2003; 16 (4):56–60.
14.
NahataMC. Pharmacist's role in health care [editorial]. Ann Pharmacother2002; 36:527–9.
Welcome to Capital Health [website]. Halifax: Capital Health. Available: www.cdha.nshealth.ca/ (accessed August 31, 2004).
17.
Physician search [online database]. Halifax: College of Physicians and Surgeons of Nova Scotia; updated May 13, 2005. Available: http://server1.kljsolutions.com/pr2/search.asp (accessed May 17, 2005).
18.
Pharmacy Association of Nova Scotia — welcome [home page]. Halifax: The Association. Available: www.pans.ns.ca/ (accessed July 12, 2003).
CMA policy summary. Approaches to enhancing the quality of drug therapy. A joint statement by the CMA and the Candian Pharmaceutical Association. CMAJ1996;155(6):784A-C.
27.
BradshawSJDoucetteWR. Community pharmacists as patient advocates: physician attitudes. J Am Pharm Assoc1998; 38 (5):598–602.
28.
RanelliPLBissJ. Physician's perceptions of communication with and responsibilities of pharmacists. J Am Pharm Assoc2000; 40 (5):625–30.
29.
American College of Physicians, American Society of Internal Medicine. Pharmacist scope of practice [position paper]. Ann Intern Med2002;136:79–85.
30.
MacKinnonNJZwickerLA. Review of seamless care — backgrounder. In: MacKinnonNJ editor. Seamless care: a pharmacist's guide to continuous care programs. Ottawa: Canadian Pharmacists Association; 2003:1–12.
31.
DossaA. Overcoming barriers to seamless care. In: MacKinnonNJ, editor. Seamless care: a pharmacist's guide to continuous care programs. Ottawa: Canadian Pharmacists Association; 2003:19–29.
32.
BanduraA. Self-effiacy theory: toward a unifying theory of behavioral change. Psychol Rev1977; 84 (2):191–215.
33.
AjzenI. The theory of planned behavior. Organ Behav Hum Decis Process1991; 50:179–211.
